Drug intelligence / Profile preview

HRS8807

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS8807 is an investigational small molecule drug developed by Shanghai Hengrui Pharmaceutical for the treatment of ER-positive, HER2-negative metastatic or locally advanced breast cancer. It acts as a selective estrogen receptor covalent antagonist (SERCA), targeting the estrogen receptor to inhibit its activity in hormone receptor–positive breast cancer. The drug is administered orally and has shown early signs of robust antitumor activity and favorable pharmacokinetic properties in phase 1 clinical trials. As of now, it remains in early-stage development with no approved indications[1][2][6].

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on HRS8807.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS8807.

Explore the full profile